SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication
- PMID: 33723254
- PMCID: PMC7960988
- DOI: 10.1038/s41467-021-21903-z
SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication
Abstract
The recently identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic. How this novel beta-coronavirus virus, and coronaviruses more generally, alter cellular metabolism to support massive production of ~30 kB viral genomes and subgenomic viral RNAs remains largely unknown. To gain insights, transcriptional and metabolomic analyses are performed 8 hours after SARS-CoV-2 infection, an early timepoint where the viral lifecycle is completed but prior to overt effects on host cell growth or survival. Here, we show that SARS-CoV-2 remodels host folate and one-carbon metabolism at the post-transcriptional level to support de novo purine synthesis, bypassing viral shutoff of host translation. Intracellular glucose and folate are depleted in SARS-CoV-2-infected cells, and viral replication is exquisitely sensitive to inhibitors of folate and one-carbon metabolism, notably methotrexate. Host metabolism targeted therapy could add to the armamentarium against future coronavirus outbreaks.
Conflict of interest statement
V.K.M. and B.E.G. are listed as inventors on a patent application filed by the Broad Institute based on results from this manuscript. V.K.M. is on the scientific advisory board and receives compensation from Janssen Pharmaceuticals and 5am Ventures and owns equity in Raze Therapeutics. B.E.G. receives research support from Abbvie. S.J.E. is a founder of TSCAN Therapeutics, MAZE Therapeutics, and Mirimus. S.J.E. is a founder of TSCAN Therapeutics, MAZE Therapeutics, ImmuneID, and Mirimus. S.J.E. serves on the scientific advisory board of Homology Medicines, TSCAN Therapeutics, MAZE Therapeutics, XChem, and is an advisor for MPM, none of which affect this work. Y.Z., R.G., S.H.K., H.S., S.Z., J.H.L., Y.F., M.G., C.N.O., and D.T.H. declare no competing interests.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
